Boehringer Ingelheim, Envisagenics sign up to $1B RNA splicing oncology target deal
核心洞察
Boehringer Ingelheim will pay Envisagenics (搜索) more than $1 billion in aggregate potential payments under a multi-year research collaboration and option agreement in solid tumors.
Envisagenics (搜索) will use its AI-powered SpliceCore (搜索) platform, built on more than 14 million RNA splicing events, to identify and validate tumor-specific targets.
Boehringer gains options to exclusively license validated targets for development across antibody-drug conjugates, T-cell engagers and multispecific antibodies.
Boehringer Ingelheim has entered a multi-year research collaboration and option agreement with New York-based Envisagenics (搜索) to identify and validate tumor-specific targets derived from alternative RNA splicing for use in solid tumor therapies. Envisagenics is eligible to receive more than USD 1 billion in aggregate payments, comprising an upfront payment, research funding, option fees, development, regulatory and commercial milestones, and royalties on future product sales.
The specific upfront amount, individual milestone values, option fees, royalty rates, deal duration and geographic scope were not disclosed. The USD 1 billion figure represents the maximum aggregate potential across all payment categories if options are exercised and milestones are achieved across multiple targets.
Searching splicing for tumor-specific isoforms
Under the agreement, Envisagenics (搜索) will apply its AI-powered SpliceCore (搜索) platform to identify and validate tumor-specific targets. The company describes the platform as screening more than 14 million distinct RNA splicing events to predict disease specificity, patient prevalence and therapeutic suitability, combining artificial intelligence, large-scale transcriptomics and experimental validation.
The scientific premise is that one gene does not necessarily produce one protein. During RNA splicing, cells can assemble RNA transcripts in different ways, producing multiple protein variants, or isoforms, from the same gene. In cancer that process is often disrupted, and the resulting isoforms can be more specific to tumor cells than the normal version of the protein, potentially giving drug developers targets that spare healthy tissue. Altered splicing has also been linked to mechanisms cancer cells use to develop drug resistance.
That approach shifts the role of AI further upstream, using algorithms to find new targets rather than primarily to optimize or characterize known ones. Alternative splicing can generate tumor-specific protein isoforms that are absent or less abundant in healthy tissue, potentially expanding the pool of selectively targetable antigens.
Modalities and licensing structure
Boehringer Ingelheim will have the option to exclusively license selected validated targets for downstream development and commercialization across multiple modalities, including antibody-drug conjugates (ADCs), T-cell engagers (TcEs) and multispecific antibodies. The agreement covers selected oncology targets identified through the collaboration.
The deal fits Boehringer's broader oncology strategy of combining new biological targets with different therapeutic modalities. In April 2025 the German drugmaker partnered with Tessellate Bio (搜索) to explore synthetic lethality in tumors using alternative lengthening of telomeres, and six months later it teamed up with South Korea's AimedBio (搜索) to develop an ADC against a tumor-specific marker. Its internal pipeline is also increasingly biomarker-driven: in June, Boehringer started three Phase 3 oncology trials, two testing the DLL3 (搜索)-targeted T-cell engager obrixtamig and another testing the HER2 (搜索) inhibitor zongertinib. The Envisagenics (搜索) deal also follows a September 2026 agreement giving Boehringer access to Owkin (搜索)'s K Pro AI platform and multimodal patient data across oncology and immunology.
Envisagenics' platform and pipeline
Envisagenics (搜索) was founded in 2014 as a Cold Spring Harbor Laboratory (搜索) spinout and was an early adopter of the combination of RNA sequencing, alternative splicing and AI. The company initially operated mainly as a bioinformatics business before moving computational findings into its own laboratory for experimental validation four years after its launch.
It has previously worked with Johnson & Johnson, Biogen and Bristol Myers Squibb (搜索), which partnered with Envisagenics (搜索) in 2022 to identify splicing-derived oncology targets. A 2021 Series A was led by Red Cell Partners, with investors including Microsoft's M12 and Madrona Venture Group. Bristol Myers Squibb joined its Series B as a strategic investor in 2024; Envisagenics did not disclose the size of that round, although external databases put it at about $25 million.
Envisagenics (搜索) separately continues to advance wholly owned programs. Its lead program, ENV-375 (搜索), is a preclinical antisense therapy for ALS, while its oncology work includes targets for ADCs, T-cell engagers, multispecific antibodies and radioligands.
The Boehringer partnership is now a test of whether Envisagenics (搜索) can turn its large computational search space into targets that survive biological validation.